United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Sells 41,429 Shares of Danaher Co. (NYSE:DHR)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund decreased its holdings in Danaher Co. (NYSE:DHR) by 35.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 74,747 shares of the conglomerate’s stock after selling 41,429 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Danaher were worth $17,158,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. Howard Capital Management Group LLC boosted its holdings in shares of Danaher by 4.1% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after buying an additional 48 shares during the period. Great Valley Advisor Group Inc. increased its position in Danaher by 3.8% during the 3rd quarter. Great Valley Advisor Group Inc. now owns 1,646 shares of the conglomerate’s stock worth $458,000 after buying an additional 61 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Danaher by 212.5% during the third quarter. Larson Financial Group LLC now owns 2,753 shares of the conglomerate’s stock worth $765,000 after buying an additional 1,872 shares in the last quarter. Harvest Fund Management Co. Ltd grew its stake in shares of Danaher by 544.6% in the third quarter. Harvest Fund Management Co. Ltd now owns 954 shares of the conglomerate’s stock valued at $265,000 after acquiring an additional 806 shares in the last quarter. Finally, DRW Securities LLC increased its position in Danaher by 100.1% during the third quarter. DRW Securities LLC now owns 3,081 shares of the conglomerate’s stock worth $857,000 after acquiring an additional 1,541 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of NYSE:DHR opened at $212.36 on Wednesday. The stock’s 50 day moving average is $216.41 and its 200-day moving average is $237.75. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $151.78 billion, a price-to-earnings ratio of 40.22, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the business earned $2.09 EPS. Sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.60%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio is 24.24%.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Citigroup decreased their price target on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Jefferies Financial Group decreased their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research note on Friday, December 13th. Finally, The Goldman Sachs Group raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price target on the stock in a report on Friday, March 21st. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $278.24.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.